27th January 2016
MSP customer, Premaitha Health PLC, is expanding into international markets having signed two new service contracts with customers in Armenia and Republic of Moldova. Premaitha Health developed the pioneering IONA® test – the first CE-marked non-invasive prenatal screening (NIPT) product. These new contracts will enable more pregnant women to benefit from the safety and accuracy of NIPT.
Dr Stephen Little, CEO of Premaitha said: “We are pleased to see our international footprint increase as demand for NIPT using the IONA® test grows. The high clinical standards and excellent customer support offered by Premaitha’s screening services team, coupled with the proven performance of the IONA® test means that we are able to provide pregnant women with the best possible screening test.”
Premaitha initiated its Care Quality Commission (CQC) registered NIPT screening service in July 2015 and in October opened a dedicated facility in response to customer demand for the IONA® test. The laboratory provides a routine NIPT screening service for many of its customers as well as an interim solution for those keen to start offering NIPT whilst establishing their own IONA® laboratory in-house.